NASDAQ:ORMP - Oramed Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.95 -0.17 (-5.45 %) (As of 05/22/2019 01:49 PM ET)Previous Close$3.12Today's Range$2.95 - $3.0252-Week Range$2.78 - $8.59Volume221 shsAverage Volume62,424 shsMarket Capitalization$51.27 millionP/E RatioN/ADividend YieldN/ABeta1.15 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes. It is also developing a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York. Receive ORMP News and Ratings via Email Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ORMP Previous Symbol CUSIPN/A CIK1176309 Webhttp://www.oramed.com/ Phone646-844-1164Debt Debt-to-Equity RatioN/A Current Ratio5.80 Quick Ratio5.80Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.45 million Price / Sales20.93 Cash FlowN/A Price / Cash FlowN/A Book Value$1.79 per share Price / Book1.65Profitability EPS (Most Recent Fiscal Year)($0.86) Net Income$-12,720,000.00 Net Margins-593.74% Return on Equity-59.96% Return on Assets-36.51%Miscellaneous EmployeesN/A Outstanding Shares17,381,000Market Cap$51.27 million Next Earnings Date7/11/2019 (Estimated) OptionableOptionable Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions What is Oramed Pharmaceuticals' stock symbol? Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP." When is Oramed Pharmaceuticals' next earnings date? Oramed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, July 11th 2019. View Earnings Estimates for Oramed Pharmaceuticals. What price target have analysts set for ORMP? 2 brokers have issued twelve-month target prices for Oramed Pharmaceuticals' shares. Their forecasts range from $25.00 to $25.00. On average, they anticipate Oramed Pharmaceuticals' stock price to reach $25.00 in the next year. This suggests a possible upside of 747.5% from the stock's current price. View Analyst Price Targets for Oramed Pharmaceuticals. What is the consensus analysts' recommendation for Oramed Pharmaceuticals? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oramed Pharmaceuticals. Has Oramed Pharmaceuticals been receiving favorable news coverage? Media stories about ORMP stock have been trending neutral on Wednesday, according to InfoTrie. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Oramed Pharmaceuticals earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. Who are some of Oramed Pharmaceuticals' key competitors? Some companies that are related to Oramed Pharmaceuticals include Spero Therapeutics (SPRO), Affimed (AFMD), Galectin Therapeutics (GALT), Recro Pharma (REPH), Synlogic (SYBX), Aldeyra Therapeutics (ALDX), Aeglea Bio Therapeutics (AGLE), VBI Vaccines (VBIV), Acer Therapeutics (ACER), CELYAD SA/ADR (CYAD), Syndax Pharmaceuticals (SNDX), Avid Bioservices (CDMO), Kala Pharmaceuticals (KALA), Chiasma (CHMA) and Poxel (PXXLF). What other stocks do shareholders of Oramed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Andrea Electronics (ANDR), Pluristem Therapeutics (PSTI), Mateon Therapeutics (MATN), Caladrius Biosciences (CLBS) and Gilead Sciences (gild). Who are Oramed Pharmaceuticals' key executives? Oramed Pharmaceuticals' management team includes the folowing people: Mr. Nadav Kidron, CEO, Pres & Exec. Director (Age 45)Dr. Miriam Kidron, Chief Scientific Officer, Chief Medical & Technology Officer and Director (Age 79)Ms. Hilla Eisenberg CPA, CFO, Treasurer & Sec. (Age 35)Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board Who are Oramed Pharmaceuticals' major shareholders? Oramed Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (3.92%) and Renaissance Technologies LLC (0.60%). Company insiders that own Oramed Pharmaceuticals stock include Aviad Friedman, Nadav Kidron and Xiaopeng Li. View Institutional Ownership Trends for Oramed Pharmaceuticals. Which institutional investors are selling Oramed Pharmaceuticals stock? ORMP stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for Oramed Pharmaceuticals. Which institutional investors are buying Oramed Pharmaceuticals stock? ORMP stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Oramed Pharmaceuticals stock in the last two years include Aviad Friedman and Xiaopeng Li. View Insider Buying and Selling for Oramed Pharmaceuticals. How do I buy shares of Oramed Pharmaceuticals? Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Oramed Pharmaceuticals' stock price today? One share of ORMP stock can currently be purchased for approximately $2.95. How big of a company is Oramed Pharmaceuticals? Oramed Pharmaceuticals has a market capitalization of $51.27 million and generates $2.45 million in revenue each year. The biotechnology company earns $-12,720,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. What is Oramed Pharmaceuticals' official website? The official website for Oramed Pharmaceuticals is http://www.oramed.com/. How can I contact Oramed Pharmaceuticals? Oramed Pharmaceuticals' mailing address is 142 W. 57TH STREET 11TH FLOOR, NEW YORK NY, 10019. The biotechnology company can be reached via phone at 646-844-1164 or via email at [email protected] MarketBeat Community Rating for Oramed Pharmaceuticals (NASDAQ ORMP)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 243 (Vote Outperform)Underperform Votes: 137 (Vote Underperform)Total Votes: 380MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote "Outperform" if you believe ORMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/22/2019 by MarketBeat.com StaffFeatured Article: Forex Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.